It should be a criminal offense if an insurance company is responsible for a delay in a policyholder's necessary health care.
Withholding prescribed treatments, even for just a day, can be anywhere from inconvenient to catastrophic for the victim. Medical providers may not withhold necessary treatment from any patient on any grounds, as it is their duty to provide it-- it should be justly illegal for any "middle man" to interfere with a medical provider's legal and ethical obligation to treat a patient.
Severity of the charge and its legal consequences should depend upon the scope of the offense (length of delay) and its consequences to the victim (impact on the person).
The testimonies of the victim, the pharmacy, and the medical provider who prescribed the treatment should be key considerations for the determination. Additional important testimony should come from the victim's other medical providers, housemates, family, educators/mentors, colleagues/coworkers, or employers.
The charge should become criminal record for the company. The company (perhaps the agent's office) should be fined per day delayed.
Some taxation can be applied; just to pay off the folks who do the filing, advocacy, testimony, processing. A hefty majority of the fine should be compensation owed to the victim.
If delays became a criminal charge on companies' records, then companies would have a strong motive to terminate agents who aren't performing with punctuality. It would become their best financial interest to invest only in timely agents who would, in turn, gain a best interest to invest only in timely subordinates.
I posit that insurance delays would wane significantly, resulting in more timely delivery of treatments to policyholders, and many people's qualities of life would improve drastically for it.
90 notes
·
View notes
i agree with ur sasuke take,,,, like i think the series has a LOTTT of flaws but i don’t think sasuke finally finding some relief from his lifelong grief in the love he has for naruto (which is reciprocated) and being able to rekindle his hope for a better world without a need for personal eternal sacrifice is one of them tbh.
Yes I agree. I agree 100%, just genuinely curious, what post made you think I disagree?
If it's the latest one referencing the v for Vendetta, that exactly proves my point.
My point is that Naruto cares about the man.. the human being that is sasuke. Naruto wants sasuke first and foremost to be happy and at peace.
(Vs readers of the story that can disengage and see sasuke as a fictitious character wish to see sasuke continue to push his mental limits and continue his quest for vengeance even while seeing how it's hurting him inside)
Naruto doesn't see sasuke as a pawn for social justice, or a character to project his ideals for political revolution onto. Rather he sees him as a human being in pain and he wants to carry that pain with him... It's ... The love between Naruto and Sasuke is so beautiful. It's not a mistake at all.
Sorry is this refering to another post?
15 notes
·
View notes
Urgent action is required to better understand and more effectively manage drought risk to reduce the devastating toll on human lives and livelihoods, and ecosystems.
Official high-level launch of the Global Assessment Report for Disaster Risk Reduction Special Report on Drought 2021 (GAR SRD2021)
Droughts have deep, widespread and underestimated impacts on societies, ecosystems, and economies. They incur costs that are borne disproportionately by the most vulnerable people. As we move towards a 2˚C warmer world, urgent action is required to better understand and more effectively manage drought risk to reduce the devastating toll on human lives and livelihoods, and ecosystems.
The GAR Special Report on Drought 2021 explores the systemic nature of drought and its impacts on achievement of the Sendai Framework for Disaster Risk Reduction, the SDGs and human and ecosystems health and wellbeing.
The GAR Special Report on Drought 2021 will be launched on 17 June 2021, the World Day for Combating Desertification and Drought in conjunction with the UN Convention to Combat Desertification.
2 notes
·
View notes
Navigating the Genetic Landscape of Blood Cancers: Innovations in Diagnosis and Treatment - Technology Org
New Post has been published on https://thedigitalinsider.com/navigating-the-genetic-landscape-of-blood-cancers-innovations-in-diagnosis-and-treatment-technology-org/
Navigating the Genetic Landscape of Blood Cancers: Innovations in Diagnosis and Treatment - Technology Org
In an era where precision medicine is swiftly becoming the gold standard, the battle against rare blood cancers, known as myeloproliferative neoplasms (MPNs), is advancing with remarkable sophistication. Renowned health organisations, including the World Health Organisation and the International Consensus Classification, have emphasised the crucial role of identifying mutations in specific genes such as JAK2, MPL, and CALR. This focus is particularly pivotal for diagnosing MPNs that do not show the Philadelphia chromosome, a hallmark for some types of leukaemia, underscoring a nuanced approach to tackling these complex diseases.
A blood test. Image credit: U.S. Air Force photo by Staff Sgt. Teresa J. Cleveland, Public Domain via Health.mil
Strategic mutation detection: Guiding the way forward
The National Comprehensive Cancer Network provides a structured framework for testing, guiding physicians through a meticulous process of mutation detection. Initially, the focus is on identifying mutations in a particular segment of the JAK2 gene. If suspicions of MPN persist, the testing scope expands to include CALR and MPL mutations, particularly for suspected cases of essential thrombocythemia or primary myelofibrosis. For individuals possibly facing polycythaemia vera (PV), a distinct MPN form, analysis of a different section of the JAK2 gene becomes imperative.
Diverging pathways: BCR-ABL and beyond
The quest to understand and categorise these disorders has led to the division of molecular laboratory investigations into two critical pathways, mirroring the complexity and specificity of the diseases themselves.
Firstly, there are tests aimed at detecting the BCR-ABL rearrangement – BCR-ABL quantitative polymerase chain reaction (qPCR) – a genetic hallmark of chronic myeloid leukaemia (CML). This particular type of MPN is defined by the presence of the Philadelphia chromosome, a product of this rearrangement, and signifies a distinct category within the MPN spectrum. The identification of the BCR-ABL gene through molecular diagnostics is not just a matter of classification; it directly influences the treatment strategy. Patients with this rearrangement are typically treated with tyrosine kinase inhibitors (TKIs), which target the abnormal protein produced by the BCR-ABL gene.
On the other side of the diagnostic divide are the tests designed to identify mutations in the driver genes of Philadelphia chromosome-negative (Ph-negative) MPNs. This category encompasses a variety of conditions, including PV, essential thrombocythemia (ET), and primary myelofibrosis (PMF), each associated with mutations in genes such as JAK2, CALR, and MPL. Unlike their BCR-ABL-positive counterpart, these Ph-negative MPNs require a different approach to diagnosis and treatment, relying on the identification of these specific mutations to guide therapeutic decisions.
Early Detection through advanced technologies
This detailed diagnostic pathway is integral to a larger story of innovation within haematology laboratories, where tools such as qPCR and digital PCR (dPCR) facilitate the early identification of key mutations at low variant allele frequencies (VAF). These advancements enable the detection of disease markers years, sometimes decades, before the clinical onset of haematological malignancies, tracing some mutations back to as early as childhood or even prenatal stages. Early mutations detected in conditions ranging from the asymptomatic “pre-MPN” phase to overt MPN highlight the disease progression continuum and underscore potential intervention opportunities.
Precision in genetic testing and its implications
In the area of Ph-negative MPNs, the accuracy of genetic testing is increasingly crucial. The World Health Organisation emphasises the critical role of identifying the JAK2 V617F mutation as a core diagnostic criterion for PV, ET, and PMF. However, the story extends beyond mere detection; quantifying this mutation is pivotal for patient management and prognostication.
The implications are significant: a higher VAF of the JAK2 V617F mutation correlates with a more aggressive disease course, including intensified symptoms in PV, an elevated risk of serious blood clots in ET, and accelerated progression in PMF. This insight shifts the focus towards a more refined, personalised approach to cancer treatment, where the mutation’s quantity may unlock the potential for more effective, targeted therapies.
The role of dPCR and NGS in advancing diagnosis
Traditionally, allele-specific qPCR has been the benchmark for measuring JAK2 V617F mutation levels, praised for its sensitivity and specificity. It has allowed clinicians to both detect and quantify mutations, informing therapeutic strategies. Enter dPCR, an innovative technology set to revolutionise this standard. dPCR excels in providing absolute quantification of the JAK2 V617F mutation without the need for standard curves, offering unmatched precision in assessing mutation load. The benefits are considerable, providing a clearer pathway for therapeutic decision-making.
Comparative studies affirm the high concordance between qPCR and dPCR, reinforcing confidence in the accuracy of these methods. dPCR’s precision is transformative, enabling precise measurement of mutation levels and potentially revolutionising patient care. Beyond this precision, the integration of next-generation sequencing (NGS) into diagnostic practices expands the horizon. NGS doesn’t merely assess the JAK2 V617F mutation but provides a comprehensive view of the genetic landscape, revealing a range of mutations that could affect disease progression and treatment response. This broadened perspective marks a new chapter in personalised medicine, where treatment can be customised to each patient’s unique genetic profile.
A new paradigm in MPN management
As we find ourselves at this crossroads, the amalgamation of dPCR, NGS, and conventional diagnostic approaches is forging a new standard in MPN management. This represents not merely progress but a significant leap towards a future where treatment is not only targeted but also transformative. The implications are vast, heralding a new era in cancer treatment where precision in diagnosis and treatment personalisation converge, offering hope to those facing these daunting diseases. In this evolving field, the promise of improved patient outcomes and quality of life is not just a hopeful prospect—it is an imminent reality, signalling a new dawn in cancer care.
0 notes
Launch of the Gender Action Plan to support implementation of the Sendai Framework for Disaster Risk Reduction 2015-2030 (CSW68 Side Event).
The Sendai Framework for Disaster Risk Reduction 2015-2030 (Sendai Framework) seeks to "prevent new and reduce existing disaster risk through the implementation of integrated and inclusive economic, structural, legal, social, health, cultural, educational, environmental, technological, political and institutional measures that prevent and reduce hazard exposure and vulnerability to disaster, increase preparedness for response and recovery, and thus strengthen resilience."
Watch of Launch of the Gender Action Plan to support implementation of the Sendai Framework for Disaster Risk Reduction 2015-2030 (CSW68 Side Event)
Objectives of the event The event will:
Launch the Gender Action Plan to Support Implementation of the Sendai Framework for Disaster Risk Reduction 2015-2030 (Sendai GAP)
Showcase good practices in gender-responsive disaster risk reduction
Provide an opportunity for key stakeholders to make commitments of support to implement the Sendai GAP.
Related Sites and Documents
The Sendai Framework for Disaster Risk Reduction 2015-2030
Concept Note
0 notes